1. PCP Perspectives Pathophysiologic Principles in the Management of Hyperkalemia

3. Fluid and Electrolyte Balance Under Tight Control

4. Electrolyte Movement Between Compartments

5. Serum Potassium Homeostasis and Regulation

7. Introduction to Hyperkalemia

8. Predictors of Hyperkalemia[a]

9. Hyperkalemia Management

10. Acute Management of Hyperkalemia

11. Standard Care of Chronic Hyperkalemia

12. High–Potassium-Containing Foods

13. Other Hidden Sources of Potassium

14. Medications Associated With Hyperkalemia

15. Diuretic Use in the Management of Chronic Hyperkalemia

16. GI Tract Cation Concentration

17. Sodium Polystyrene Sulfonate

18. Patiromer

19. Opal-HK Phase 3 Trial Study Design

20. Initial Treatment Phase Demographics and Baseline Characteristics

21. Baseline RAAS Inhibitor and Diuretic Medications

22. Initial Treatment Phase Primary and Secondary Efficacy Endpoints

23. Randomized Withdrawal Phase Time to First Recurrent Hyperkalemia Event*

24. Initial Treatment Phase Adverse Events While on Patiromer

25. Investigational Potassium Binder ZS-9*

26. 2-Phase, Dose-Ranging Trial of ZS-9 Study Design

27. Potassium Levels During the Acute and Maintenance Phase

28. ZS-9 Adverse Events

29. Engaging Patients in the Management of their Chronic Disease

30. Concluding Remarks

31. Abbreviations

32. Abbreviations